10.1016/S1044-7431(03)00160-X [DOI] [PubMed] [Google Scholar] Komada M., Hatsuzawa K., Shibamoto S., Ito F., Nakayama K., Kitamura N
FDA PCAC 2023 For sourcing guidance and vendor evaluation criteria, see our recommended sources page
While its therapeutic potential is substantial, further investigation is warranted to elucidate its pharmacokinetic profile, optimise dosing regimens, and evaluate its long-term safety and efficacy in veterinary species.
Perform a patch test first and discontinue if persistent irritation develops
The common inflammatory indicator MMP-12 exhibits elevated expression levels as individuals age, whereas AD patients skin shows the opposite trend
Suitability depends on individual skin concerns and medical evaluation